LMNX Related Analyst Ratings
-
Leerink Swann Downgrades Fluidigm Corporation (FLDM) to Market Perform
-
UPDATE: Wedbush Starts Luminex (LMNX) at Neutral; Lost Traction at Labcorp
-
Leerink Swann Boosts Valuation Ragne on Luminex (LMNX)
-
Cowen Downgrades Luminex (LMNX) to Underperform
-
UPDATE: UBS Upgrades Luminex (LMNX) to Buy; Summer Sell-off Overdone
-
Cowen Upgrades Luminex (LMNX) to Neutral
-
William Blair Downgrades Luminex (LMNX) to Market Perform
-
Piper Jaffray Upgrades Luminex (LMNX) to Neutral
-
Leerink Swann Upgrades Luminex (LMNX) to Outperform; Positive on GenturaDx and FDA Clearance of GPP
-
JPMorgan Upgrades Luminex (LMNX) to Neutral
-
GARP Research Maintains a 'Buy' on Luminex (LMNX); Q1 Review
-
UBS Maintains a 'Neutral' on Luminex (LMNX); Raising Guidance on Good '12 Start
-
Leerink Swann Downgrades Luminex (LMNX) to Market Perform; Downside to Street Expectations
-
JPMorgan Downgrades Luminex (LMNX) to Underweight
-
UBS Maintains 'Neutral' on Luminex (LMNX); Strong 2Q, Increasing Momentum
-
Jefferies Boosts Numbers on Luminex (LMNX), Maintains Hold
-
GARP's Best Ideas Q3 Edition
-
Leerink Swann Upgrades Luminex (LMNX) to Outperform Following EraGen Acquisition
-
UBS Maintains a 'Neutral' on Luminex (LMNX); Strong Consumable Sales Lead To Q1 Beat
-
Jefferies Lifts Estimates and Price Target On Luminex (LMNX)
-
Jefferies Resumes Coverage on Luminex (LMNX) at Hold, Price Target $16
-
UBS Maintains a 'Neutral' on Luminex (LMNX); Solid Finish to 2010
-
GARP Research Reiterates a 'Buy' on Luminex (LMNX); Molecular Diagnostics’ Top Line Contribution May Double Over Next 3 Years
-
William Blair Upgrades Luminex (LMNX) to Outperform
-
Stephens & Co Upgrades Luminex (LMNX) to Overweight
-
Canaccord Adams Reiterates a 'Buy' on Luminex (LMNX); Raises PT & Estimates
-
Natixis Bleichroeder Upgrades Luminex (LMNX) to Buy
-
Jefferies Starts Luminex (LMNX) at Buy
-
William Blair Initiates Coverage on Luminex (LMNX) with a Market Perform
-
Northland Securities Initiates Coverage on Luminex (LMNX) with an Outperform
-
First Analysis Upgrades Luminex (LMNX) to Overweight
-
Piper Jaffray Initiates Coverage on Luminex (LMNX) with a Neutral
-
UBS Initiates Coverage on Luminex (LMNX) with a Neutral
-
Cowen & Co Initiates Coverage on Luminex (LMNX) with a Neutral; Upside Potential, But Reflected In Premium Valuation
-
Matrix USA Rating Changes 10/08
-
Thomas Weisel Downgrades Luminex (LMNX) to Market Weight
-
JPMorgan Starts Luminex (LMNX) at Neutral
-
Jesup & Lamont Downgrades Luminex (LMNX) to Neutral
-
Matrix USA Rating Changes 1/18
-
Matrix USA Research Rating Changes: 09/26
-
Canaccord Adams Initiates Coverage on Luminex (LMNX) with a Buy
-
Thomas Weisel Starts Luminex (LMNX) at Overweight
-
Soleil Securities upgrades Luminex (LMNX) to Buy
-
Soleil Securities downgrades Luminex (LMNX) to Hold
-
House and Senate Negotiators agreed on $2.3B Avian Flu Funding - Analyst
-
Brean Murray Starts LMNX at Buy
Back to LMNX Stock Lookup
